Intellia Therapeutics Inc buy JPMorgan Chase & Co.
Start price
31.03.23
/
50%
€33.87
Target price
31.03.24
€72.55
Performance (%)
-24.45%
End price
01.04.24
€25.59
Summary
This prediction ended on 01.04.24 with a price of €25.59. The price of Intellia Therapeutics Inc has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -24.45%. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Intellia Therapeutics Inc | 4.313% | 4.313% | 105.281% | -61.338% |
| iShares Core DAX® | 0.080% | 8.288% | 12.701% | 48.797% |
| iShares Nasdaq 100 | 3.103% | 8.871% | 40.977% | 92.800% |
| iShares Nikkei 225® | -0.475% | 12.646% | 45.337% | 60.976% |
| iShares S&P 500 | 1.988% | 6.691% | 30.973% | 65.640% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at JPMorgan Chase & Co. from $82.00 to $79.00. They now have an "overweight" rating on the stock.
Ratings data for NTLA provided by MarketBeat
In the thread Trading Intellia Therapeutics Inc
Die von JPMorgan_Chase___Co_ gewählte maximale Laufzeit wurde überschritten
Stopped prediction by JPMorgan_Chase___Co_ for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€19.93
12.08.24
12.08.24
€50.28
12.08.25
12.08.25
-53.83%
13.08.25
13.08.25
